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Abstract
The role of biomarkers has increased in cancer clinical trials such that novel designs are needed to 
efficiently answer questions of both drug effects and biomarker performance. We advocate 
Bayesian hierarchical models for response-adaptive randomized phase II studies integrating single 
or multiple biomarkers. Prior selection allows one to control a gradual and seamless transition 
from randomized-blocks to marker-enrichment during the trial. Adaptive randomization is an 
efficient design for evaluating treatment efficacy within biomarker subgroups, with less variable 
final sample sizes when compared to nested staged designs. Inference based on the Bayesian 
hierarchical model also has improved performance in identifying the sub-population where 
therapeutics are effective over independent analyses done within each biomarker subgroup.
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1. Introduction
Clinical trials in cancer are designed to rigorously monitor and assess health interventions, 
whether as observational studies or randomized controlled trials. With expansive research in 
tumor biology over the past decades, cancer has increasingly been recognized as a 
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biologically heterogeneous disease (Golub et al., 1999; Perou et al., 2000; Vogelstein and 
Kinzler, 2004). Tissue and specimen collection are now commonplace in therapeutic trials, 
to answer correlative scientific objectives about the disease process and patient-specific 
responses. At the same time, the availability and decreasing costs of high-throughput 
technologies have enabled the evaluation of the entire genome, and of other cellular 
compartments such as the transcriptome, proteome, metabolome, or secretome, and has 
vastly increased the amount of molecular data derived from biospecimen. Guidelines have 
been issued on the collection and use of biospecimen for biomarker development (McShane 
et al., 2005; Schmitt et al., 2004; Simon et al., 2009); and ultimately, the molecular 
characterization of tumors has been postulated as providing information at the individual 
patient level to optimize care, and be a critical component of personalized medicine 
(Hamburg and Collins, 2010).
Biomarkers are broadly defined as chemical, physical, or biological assessments used as an 
indicator of a patients disease state. Their application in medicine is delineated as: 
prognostic markers providing information about the overall risk of a clinical outcome (e.g., 
cancer recurrence); or predictive markers providing information about the specific effect of 
a therapeutic intervention (e.g., response to a targeted therapy, or treatment-related toxicity). 
Many laboratory-based assays have been proposed as prognostic or predictive biomarkers of 
cancer (Ross et al., 2003; Amado et al., 2008), and some have been shown to have both 
prognostic and predictive value in specific clinical settings (Albain et al., 2010). Molecular 
assays can also serve as surrogate markers when they correlate with clinical outcomes of 
primary interest (e.g., overall survival). Thus, they can substitute as an earlier endpoint for 
evaluating therapeutic benefit, or be incorporated into the design that directs ongoing 
treatment regimen. For example, based on the results of ACOSOG Z1031 (Ellis et al., 2011), 
Ki-76 is proposed in the neoadjuvant ALTERNATE trial as a surrogate for response so that 
it directs the treatment course of patients on trial (DeCensi et al., 2011).
Traditionally, the predictive and prognostic value of molecular assays have been 
investigated in a retrospective manner, where biospecimen are banked during the course of 
the trial and evaluated on completion. This allows for a variety of study designs, e.g., nested 
case-control that can draw from larger randomized or observational studies when clinical 
outcome is rare (Pepe et al., 2001), or when laboratory resources are limited. However, only 
a prospective application of the biotechnologies will fully evaluate their clinical utility as an 
assay. This includes the accessibility of the biospecimen, evaluation of quality control of the 
assay, and the feasibility of making determinations from the molecular output (Simon et al., 
2009).
Response-adaptive trials designs have been advocated as a way to allocate patients such that 
more patients receive the better treatment. Wei and Durham (1978) extended the stochastic 
play-the-winner process of Zelen (1969) to randomization using urn models. These 
strategies were later used in developing the randomized Polya urn (Durham et al., 1998) and 
drop-the-loser rules (Ivanova, 2003) and the concept of optimal allocation was introduced by 
Rosenberger et al. (2001). As a second general approach, the doubly adaptive biased coin 
design was introduced by Eisele and Woodroofe (1995) and was further developed by Hu 
and Zhang (2004) among others.
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Bayesian methods for clinical trials have been well established in the statistical literature. 
For interim monitoring of trials, Spiegelhalter et al. (1986) advocated the use of predictive 
power for making decisions of early stopping. The Bayesian model was also used to 
determine sample size requirements during trial development (Spiegelhalter and Freedman, 
1986). Many subsequent methods were developed for sample size determination as 
summarized in the review given by Adcock (1997). Bayesian models have been proposed 
for alternative study designs including noninferiority trials of therapeutics and medical 
devices (Spiegel-halter et al., 2004; Chen et al., 2011), seamless phase II/III designs (Inoue 
et al., 2002), and adaptive designs that drop treatment arms or modify randomization (Berry, 
2005, 2006).
Under the Bayesian paradigm, Kass and Steffey (1989) established as a class “conditionally 
independent hierarchical models” for observations drawn from distinct units (e.g., sites, 
clusters, or geographic regions). More recently, this class of models has been proposed for 
phase II and III clinical trials with integral biomarkers. Thall et al. (2003) proposed the use 
of a hierarchical model for single arm phase II trials when subjects have multiple subtypes 
of the disease. Zhou et al. (2008) extended the hierarchical structure to consider multiple 
treatments in a probit regression model for the randomized phase II trial: Biomarker-
integrated approaches of targeted therapy of lung cancer elimination (BATTLE). The book 
by Berry (2011) includes several illustrations for using hierarchical models to borrow 
information across components of a trial, and most recently, the Bayesian paradigm is used 
to consider an evolving series of novel therapeutics and biomarkers in I-SPY 2: An Adaptive 
Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy (Barker et al., 
2009).
In the following sections, we state the motivation for considering adaptive-randomization 
(AR) strategies for biomarker-driven trials in the phase II setting. Using the general notation 
of Kass and Steffey (1989) we define the Bayesian components of the trial. We then use 
simulation to summarize operating characteristics under a variety of scenarios that represent 
combinations of predictive biomarkers. In particular, we argue that informative prior 
distributions are needed for AR and interim monitoring to control treatment assignment 
early in the trial, while final evaluations of efficacy should rely on noninformative priors 
when the frequentist paradigm for inference is desired. Lastly, using a specific investigation 
of a novel targeted therapy in metastatic breast cancer, we contrast the performance of the 
adaptive approach against traditional staged designs for phase IIs nested within the 
biomarker-defined subgroups (Mandrekar and Sargent, 2010).
2. Motivation
In cancer clinical trials, the research and regulatory environment have divided the process 
for evaluating new therapeutics into four phases, with phase II and III studies designated for 
giving preliminary and definitive evidence of efficacy, respectively. For efficacy trials that 
incorporate prospective biomarkers, the National Cancer Institute has designated two types. 
Integrated studies involve assays clearly identified as part of the primary objective of a 
clinical trial, and are often intended to validate biomarkers prior to their use in future trials. 
As such, they should be hypothesis-testing in nature, and not hypothesis-generating and 
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motivated by discovery. Assays are to be performed in real time and include complete plans 
for specimen collection, laboratory measurements, and statistical analysis. Integral studies 
have many of the same elements, but are also designed such that the assay must be 
completed before patients can proceed on the trial. Examples include biomarkers to establish 
eligibility, biomarkers used for patient stratification, and biomarkers that inform treatment 
assignment. The most common trial designs with integral biomarkers are listed below, with 
representative schema in Figure 1 (Freidlin et al., 2010).
– Randomized-block designs are where the biomarker is used to define a stratification 
factor for randomization, but equivalent schemes are used within strata, such that 
globally, treatment assignment does not vary by biomarker status.
– Marker-enrichment designs are used to select a sub-population for investigation, 
whether it be a predictive marker for patient sensitivity to treatment, or prognostic 
markers to identify high-risk patients in which a new therapeutic may have the most 
clinical benefit.
– Marker-directed designs are where treatment assignment is determined by the integral 
biomarker; for example, assigning marker positive patients to the hypothesized optimal 
treatment (predictive marker), or to the more aggressive treatment (prognostic marker).
In deciding among the different integral biomarker designs, one must weigh the relative 
importance of validating the prognostic or predictive value of the biomarker, vs. using the 
information it provides to optimize efficacy of the treatments. Randomized-block designs 
provide the only direct evidence of marker performance, but are less efficient in terms of 
evaluating efficacy within target biomarker subgroups when compared to marker-directed 
designs. Conversely, it can be argued that in the phase II setting, where the goal is to provide 
evidence of efficacy for future phase III studies, marker-directed designs are restrictive in 
terms of the possible outcomes from conducting the study. A positive level of efficacy 
would lead to a randomized controlled trial within the marker subgroup, while insufficient 
levels of efficacy would not support moving to any phase III study. Based on these 
distinctions, the sensitivity and specificity of the assays should be known in advance of 
selecting between a randomized-block or marker-directed design. With this information, the 
efficiency of enrichment can be weighed against the fact that some patients who truly 
benefit from treatments would be excluded from receiving the regimen.
Because these are difficult considerations when developing phase II trials for new drugs or 
indications, we propose an adaptive strategy which allows for efficacy to be evaluated 
across all targeted subpopulations in an efficient manner. In essence, these methods allow 
for a single trial to gradually and seamlessly transition from a randomized-block design to a 
marker-directed design. As a result, more patients are randomized to optimal therapy when, 
and only when, biomarkers are predictive. The actual size of the trial will also vary less than 
a randomized-block design that uses multistage tests to reach similar levels of efficiency. 
Lastly, by using Bayesian models, trial flexibility that is induced by the data-driven 
adaptations will be taken into account in the statistical inferences.
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3. A Phase II Response-Adaptive Design
In a randomized phase II trial with integral biomarkers, suppose we have K patient 
subgroups that are mutually exclusive and exhaustive for all possible assay results. A total of 
J treatment regimens are to be considered in the randomized trial, whether they be 
designated as experimental or control arms. The primary objective is to evaluate the efficacy 
of each drug within the biomarker subgroups, i.e., a noncomparative multiarm phase II 
(Rubinstein et al., 2005; Mandrekar and Sargent, 2010).
Here, the primary clinical endpoint is considered to be a binary outcome, y ∈ {0, 1}. The 
target response rate of an effective treatment in a given subgroup will be defined as π1,jk, 
while an unacceptable response rate is defined as π0,jk. Without loss of generality, we will 
assume throughout that there are common target rates of interest:
Although we note that for prognostic markers, it may be more applicable to have different 
targets for the high- and low-risk patient subgroups.
Under the formulation of Kass and Steffey (1989), a random vector of n observations, yn, is 
conditionally independent given parameters, θ. Further, conditional on hyperparameters, φ, 
the {θi} are i.i.d., such that the elements of yn are exchangeable with a common density p(⋅).
3.1. Hierarchical Model for Binary Data
Let j denote treatment arm, j = 1 …J; and k denote biomarker group, k = 1 …K. Nested 
within treatment j and biomarker k, patients are indexed by i, i = 1 …njk, nj = Σk njk, and n = 
Σj nj. We will use n to refer to the number of patients at any point during enrollment up to a 
final sample size, N. The observed responses are denoted as
Let πijk be the response probability for yijk and a binary model with the link function θijk = 
f(πijk). The proposed hierarchical structure for multiple treatment and biomarker groups is
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with hyperparameters, φ = {α, σ2, τ2}. The variance parameter σ2 controls the extent of 
borrowing across marker groups within each treatment; α and τ2 represent the second-stage 
prior distribution to the hierarchical model.
Bayesian binary hierarchical models are well characerized, and can be implemented in 
specialized software including BUGS (Lunn et al., 2000) or JAGS (Plummer, 2008). For the 
special case of a probit model, f(⋅) = Φ−1(⋅), the Gaussian priors are conjugate such that the 
full conditional distributions have closed forms. Correcting for an error that appears in Zhou 
et al. (2008) and keeping hyperparamaters unspecified, they take the form
We provide the Gibbs sampler for the probit model in the statistical language and 
environment R (see Appendix for source code). This code was used to run the simulations 
on scalable computing resources at the author institution.
3.2. Adaptive Randomization
Because the general hypothesis is that patients with certain biomarker profiles respond 
differently to the targeted treatments, randomization is conditional on biomarker group. 
Without a prior assumption of increased efficacy of certain treatments, equal randomization 
(ER) occurs at the beginning of the trial. After at least one patient is assessed for response in 
each treatment by biomarker group {njk ≥ 1}, the trial moves to AR. Under the Bayesian 
paradigm, randomization ratios at each step in enrollment, rn, are based on posterior 
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distributions for θ. The functional relationship one chooses for θ and rn was described by 
Rosenberger (1993) as the treatment effect mapping.
Here, we formulate two mappings to 0. Let Ωk,n represent the subset of nonsuspended 
treatments for marker group k at the time of randomization for patient n. For the BATTLE 
trial, randomization was based proportionally on the posterior mean for the response rate to 
each treatment
where π̂jk,n = E[f−1(μjk)∣yn]. With noninformative priors to the model, this formulation (we 
term “ratio-mapping”) is equivalent to the sequential maximum likelihood procedure 
(Rosenberger et al., 2001). Alternatively, one could base randomization on the probability a 
treatment is superior to all others (we term “max-mapping”),
which is derived from the full posterior distribution to θ. In contrasting the two formulations, 
we note that max-mapping will always approach 1 when one therapy is superior to all 
others, whereas the value ratio-mapping approaches will depend on J, π0, and π1. For this 
reason we favor max-mapping, and is used for the proposed trial in Section 5.
One criticism of Bayesian adaptive designs is that they are unstable for small amounts of 
data. A heuristic solution is to delay AR until a fixed number of patients are enrolled, and 
Cheung et al. (2006) suggested waiting until at least 10 patients are observed for every 
group. However, for phase II trials with integral biomarkers, this will typically not be 
feasible. For instance, in the BATTLE trial AR did not begin until 97 of 255 patients were 
enrolled (Kim et al., 2011), due to the requirement that njk ≥ 1 ∀jk for the Gibbs sampler 
defined in Zhou et al. (2008). We note that even at the completion of the trial, njk < 10 in 
approximately half of the subgroups. For this reason, we advocate the use of a class of 
informative prior distributions, termed “balanced priors” : 
. By increasing τ −2, one stabilizes the model so 
that ER occurs until data is accumulated from enough patients showing a difference in 
response rates.
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3.3. Interim Monitoring of Efficacy
During AR all active treatment arms are continuously monitored in order to update 
randomization ratios. Although biomarker subgroups will assign fewer patients to 
ineffective treatments as the trial proceeds, for administrative purposes it may be valuable to 
permanently suspend treatment arms once there is sufficient evidence of ineffectiveness. 
Under the Bayesian paradigm, one can compute posterior odds or Bayes factors for 
hypotheses of ineffectiveness. Alternatively, the frequentist approach can be mirrored by 
defining a threshold for futility, and use the prior distributions and all accumulated data to 
compute credible sets for efficacy.
Decisions based on Bayesian interval estimation were proposed in Zhou et al. (2008) and 
can be generalized to binary models with f−1(μjk) as
where (1 − δL) is the size of a one-sided credible set, and Fn, jk is an indicator of suspension 
of assignment to treatment j in biomarker group k after n patients are enrolled on the trial. 
We further denote  as the cumulative event of suspension at any point in the 
trial. If all J treatments are suspended, then patients in marker group k are excluded from 
enrolling on the trial. In order to be conservative about suspension with small n, we advocate 
using informative “skeptical” priors (Spiegelhalter et al., 1994) which would be centered 
around π1 :φskep = {α =f(π1), 0 < σ−2, 0 < τ−2}.
3.4. Final Determination of Efficacy
A final evaluation is performed for all nonsuspended treatments after reaching target 
accrual, N, and once complete clinical information is obtained. Again, models can be 
contrasted using Bayes factors, or a determination of efficacy can be defined under the 
hierarchical model when a (1 – δU) sized one-sided credible set to f−1(μjk) excludes the 
unacceptable response rate,
For the final analysis, a noninformative prior where τ−2 approaches zero allows for the data 
from the trial to drive all inferences.
Using these interim and final analysis plans, there is no early stopping for highly effective 
treatments, which is analogous to frequentist staged designs as developed by Simon (1989). 
We advocate this for phase II trials, because any treatments demonstrating benefit within (or 
across) marker subgroups will have greater numbers of patients assigned, and consequently, 
a more precise declaration of efficacy in the final analysis. This provides the optimal 
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information to support the development of a phase III trial, whether it be in a general or 
selected patient population.
The main study characteristics of interest are common to noncomparative phase II designs: 
true positive and true negative findings of efficacy. Using the decision criteria noted above, 
the probabilities of making correct determinations of efficacy in each treatment and 
biomarker combination are
The complementary probabilities are analogous to the frequentist definitions of Type I and II 
error.
We can also define probabilities that are complementary to family-wise error rates, which 
relate to the chance of making correct determinations of efficacy across all marker 
subgroups where a treatment is effective (P3), or not effective (P4). Likewise, the overall 
probability of having both true positive and negative findings is their union (P5):
Operating characteristics and sample-size determinations for the proposed design can be 
determined by simulating a series of relevant scenarios to the trial design.
4. Simulation
The following are two simplified scenarios where J = K = 2 that are representative of the 
general research setting of predictive biomarkers in multiarm trials: (a) evaluating a novel 
targeted agent against standard-of-care with a single predictive biomarker; and (b) selecting 
among multiple targeted agents specific to complementary predictive biomarkers. A global 
null to each scenario would be no increased efficacy with either agent. To illustrate how 
simulation is used to tune model parameters and select sample-size, we will explore each 
scenario with true unacceptable and acceptable rates of response of (π0 = 0.25, π1 = 0.5), 
and (π0 = 0.05, π1 = 0.2).
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Characteristics are drawn from B=1000 simulations, where marker status is first sampled 
from a multinomial distribution defined by marker prevalence, p, which is here set to be p = 
(0.5, 0.5). Treatment assignment is made under the randomization scheme, and the observed 
responses are sampled as independent Bernoulli variables with {πjk}. Figure 2 displays the 
average randomization rates under the single-marker scenario for ratio- and max-mapping. 
Within each panel, trajectories are drawn for models using balanced priors: φbal = {α = 
(Φ−1(π1) + Φ−1(π0))/2, σ−2 = 1, τ−2 = 100}, or using noninformative priors with τ−1 = 0.01. 
With balanced priors, there is attenuation in the rate at which randomization approaches the 
true treatment effect to each mapping. Importantly, in subgroups where there is no increased 
efficacy, randomization ratios remain centered around 0.5 throughout enrollment. With 
ratio-mapping and balanced priors, randomization rates to the effective treatment approach 
the true ratios of 0.67 and 0.8 for π1 = 0.5 and π1 = 0.2, whereas max-mapping approaches 1 
in both cases. Lastly, Table 1 shows that with a strong balanced prior, randomization has 
minimal variation (IQR < 0.02) when the number of patients on study is very small (n = 5), 
but that an unacceptably large variation (IQR > 0.5) is seen early on with noninformative 
priors, which is only partially attenuated using a moderate prior with τ = 1.
Next, we evaluated the probabilities of truly and falsely determining efficacy (P1 and 1 – 
P2) when using the monitoring plans outlined above. Simulations focused on designs using 
balanced priors and max-mapping for randomization. By plotting P1 and 1 – P2 over a range 
of target sample sizes, one can use simulation to select the desired operating characteristics 
to a trial. For the target rates π1 = 0.5 and π0 = 0.25 we found that assessing futility with a 
threshold of δL = 0.025 and a skeptical prior: φskep = {α = (Φ−1(π1), σ2 = 1, τ−2 = 100} and 
making a final determination of efficacy using noninformative hyperprior φnon = {α = 
(Φ−1(π0), σ2 = 1, τ−2 = 0.01} and δU = 0.9 provided a good balance between controlling for 
false positive and negative results. In particular, P1 ≥ 80% and 1 – P2 ≤ 10% is achieved 
with N = 55 in the single marker scenario and with N = 59 patients in the complementary 
marker scenario. By simulating under a null of no efficacy, we note the probability of early 
stoppage before N = 55 or N = 59 is 47% and 55%, such that the average sample size would 
be 48.4 and 50.3, respectively.
We next compare our method to independent Simon “optimal” two-stage tests performed 
within a randomized-block design, as an efficient nonadaptive approach to minimize 
sample-size when treatments are ineffective. Under a null, H0 : πjk = 0.25, and powered on 
the alternative H1 : πjk = 0.5, this requires 8 subjects in the first stage and 21 subjects total 
per arm (target N = 84) in order to control Type I and II errors at 10% and 20%, 
respectively. Under the respective alternative hypotheses to the single and complementary 
marker scenarios, the expected sample sizes to the two-staged design are 57.1 and 65.4, 
respectively, and 48.7 when there is truly no efficacy with either agent. Thus, marginal 
improvements in efficiency are seen with our adaptive approach. As advantages, resources 
would need not be budgeted for the larger target sample size, and more importantly, 
considerably less variation is seen under our simulations than the actual sample sizes that 
can occur with 4 independent two-stage tests (Fig. 3).
Simulations under other true effective response rates show a slight attenuation in power 
when compared to the larger staged-tests: under π1 = 0.45, P1 ranged from 0.64 to 0.67 vs. 
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power of 0.69 with the Simon design. With a larger true effect size (π1 = 0.55), P1 ranged 
from 0.86 to 0.88 vs. power of 0.89 with a Simon design. The small differences may be due 
to P2 being slightly lower than the Type I error to the Simon design, or may be reflective of 
tuning the parameters and size of the adaptive design to optimize characteristics against the 
target response rates.
For target response rates of π0 = 0.05 and π1 = 0.2, simulations were repeated to 
parameterize the model and select samples sizes. Figure 2 and Table 2 show that informative 
balanced priors are needed to stabilize {rjk,n} early in the trial and remain 1:1 on average in 
the nontarget subgroup, and we focus on max-mapping to increase allocation to optimal 
therapy. Despite the lower event rates, similar gains in efficiency can be seen in the adaptive 
design when allowing for a higher false positive rate. Using thresholds of δL = 0.025 and δU 
= 0.8, we find that N = 74 and 71 control P1 ≥ 80% and 1 – P2 ≤ 15% for the two scenarios. 
In comparison, Simon two-stages tests would require a target N = 108 (E[N] = 70.2 and 
82.8, for the two scenarios) to control Type I and II errors at this level.
Lastly, when using noninformative priors for determinations of efficacy, the posterior means 
for the response rate are biased slightly downward for J = K = 2, as is known to occur with 
AR (Rosenberger and Lachin, 2002). At n = 100, median relative risks of 0.976 and 0.959 
are seen to π1 = 0.5 and π1 = 0.2, respectively, after randomizing patients under max-
mapping and balanced priors (Table 2). The extent of bias must be carefully considered if 
one reports Bayesian point-estimates from the hierarchical model at the completion of the 
study.
5. Example
Increasingly, both clinicians and laboratory scientists have recognized that breast cancer is a 
heterogeneous disease, which poses a challenge to the development of new therapies and to 
the appropriate application of existing treatments to individual patients. Using DNA 
microarray technology, Sorlie et al. (2001) identified five major subtypes of breast tumors, 
including basal-like, Her2 over expressing, luminal-like (including luminal A and B), and 
normal breast tissue-like. It was later shown that luminal B subtype tumors have a poor 
prognosis relative to other ER+/Her2– breast cancers, and represent a population that may 
derive benefit from novel treatments in the locally advanced setting (Bild et al., 2009).
Phosphatidylinositol 3-kinases (PI3Ks) have come to attention as both a marker of prognosis 
and a potential target for therapy in a variety of human cancers (Vanhaesebroeck et al., 
2010). Once activated, these kinases phosphorylate membrane lipids which in turn trigger a 
complex signaling cascade leading to cell cycle entry, growth, and survival. Mutations 
leading to constitutive activation of the pathway have been observed, with early studies 
reporting a 40% rate of somatic mutations in the gene in breast cancer, especially hormone 
receptor-positive breast cancer (Campbell et al., 2004). Multiple inhibitors of the PI3K 
pathway are in development that demonstrate anti-tumor activity in pre-clinical and clinical 
studies (Markman et al., 2010; Baselga et al., 2011). Among the most interesting targeted 
strategies for PI3K inhibition is the luminal B subtype of breast cancer. Although typically 
hormone receptor-positive, this subtype is more chemosensitive than luminal A breast 
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cancer (Fan et al., 2006), and recent studies implicate PI3K pathway signaling in 
proliferation and cell survival in this subtype (Bild et al., 2009). However, aberrations of 
PI3K pathway signaling are common across breast cancer subtypes, and a selection strategy 
for identifying those most likely to respond to inhibition of the PI3K pathway has not yet 
been defined.
We propose a randomized phase II to evaluate a PI3K inhibitor in advanced hormone 
refractory breast cancer patients. Activity of the agent will be assessed in combination with 
standard capecitabine in ER+/Her2– breast cancer defined by standard histological methods. 
Integral biomarkers will be used to evaluate whether increased efficacy is seen in molecular 
subgroups of greatest potential to provide a selection strategy. This includes intrinsic 
subtypes by mRNA expression and PI3K DNA sequencing, with the scientific hypothesis 
that greater efficacy is seen with either PI3K mutations over wild-type, or with luminal B 
and other subtypes relative to luminal A tumors.
The primary clinical endpoint for evaluating patient response to capecitabine alone (X) and 
capecitabine plus PI3K inhibitor (XP) will be objective response. Based on prior knowledge 
of the efficacy of capecitabine, we will consider a response rate of θ0 = 0.25 as 
unacceptable, and θ1 = 0.5 as a target level of efficacy for treatments within all marker 
subgroups.
5.1. Design and Operating Characteristics
In the Bayesian AR design, we set a threshold probability of δL = 0.01 for the futility 
monitoring, and δU = 0.9 for the threshold for concluding efficacy. The balanced, skeptical, 
and noninformative priors described above are used for randomization, interim monitoring, 
and final analysis, respectively.
One heuristic rule is applied over the AR scheme to further control enrollment to the trial. 
Since there are no interim rules for stopping for superiority, the total number of patients 
enrolled into a single treatment by subgroup will be capped at 35 to avoid oversam-pling. 
This threshold was selected under a reduced Bayesian model for a single treatment and 
single biomarker subgroup, as providing greater than 95% posterior probability of 
concluding efficacy when θ = Φ−1(π1).
Simulations were run to select a maximum target sample size based on the probabilities of 
truly and falsely concluding efficacy. Specifically, six scenarios define different 
relationships between clinical benefit of XP and the two integral biomarkers, as enumerated 
in Table 2. Based on anticipated accrual, and the length of follow-up needed to observe 
objective response, a lag of 10 patients is included into the simulation for randomization and 
interim monitoring of futility.
Table 3 shows that with a target sample size of N = 168, in all scenarios probabilities of 
falsely concluding efficacy in each ineffective treatment is less than 10%, while probabilities 
of concluding success in each effective treatment ranges from 82.1% to 92.8% varying 
largely by the marker prevalence. Across simulations, effective combinations were stopped 
at rates between 3.7% and 6.4% while ineffective treatments were stopped at some point 
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during the AR phase 17.8% to 87.3% of the time. In comparison, parallel Simon two-stage 
designs require greater maximum target sample sizes, needing to allocate 24 × 8 = 192 
patients to control Type I and II errors at 0.1 and 0.15 in every group. An even greater 
number of patients is needed to match the exact operating characteristics to each scenario 
that is given in Table 3, although the discrete binomial distribution prevents a direct 
comparison.
Finally, there is a distinctive advantage of using all available data across biomarker 
subgroups when making inferences under the hierarchical model (Table 4). For each 
scenario, the joint probabilities of correctly identifying all subgroups where XP is effective 
(P3), and where XP or X are ineffective (P4). Results are superior to independent analysis 
with the larger Simon two-stage designs. The largest improvements are see when multiple 
biomarker groups demonstrate increased efficacy. For instance, if intrinsic subtype and PI3K 
mutation are equally predictive (Scenario 5), the probability of identifying all three 
subgroups increases from 0.618 to 0.694, while under a global null (Scenario 1), the chance 
of a false discovery decreases from 54.4% down to 42.5%.
6. Discussion
We have presented a novel approach to studying the efficacy of treatments in the context of 
integral biomarkers. By adopting a Bayesian response adaptive model, flexibility in the trial 
design allows for a seamless transition from investigating agents in a general population 
toward a marker-directed strategy where patients are randomized with greater probability to 
their optimal therapy. To meet the requirements of randomized phase II studies, the model 
incorporates a continuous monitoring for futility and a final analysis of efficacy that are 
conditioned on the integral biomarkers. Simulations demonstrate the properties of the model, 
and its advantages over using parallel and independent staged designs.
Adaptive trial designs give a framework whereby the mathematical models account for 
flexibility required in phase II screening trials, and with modern computational resources the 
numerical routines can be implemented as easily as exact binomial tests. Adaptive trials do 
require a larger informatics structure to continuously monitor enrolled patients in order to 
maximize gains in efficiency. However, adaptive approaches can be seamless and do not 
require suspension of enrollment until complete outcome information is obtained and 
evaluated, thus removing a large operational barrier to the study team and common 
hindrance to study accrual with staged phase II trials.
We have shown under simulation that adapting with a Bayesian hierarchal model lowers the 
total target sample sizes over traditional designs. Further, in staged designs, interim looks 
that occur early in the trial to optimize the characteristics can cause wide variations in final 
sample sizes. Flexibility and robust performance of our Bayesian AR model is demonstrated 
by the consistent operating characteristics seen across a variety of relationships between 
treatment efficacy and biomarker subgroups. Conversely, it may not be feasible to use 
parallel multistage tests for biomarker groups with unequal prevalence. We also propose that 
adaptive designs will be more robust to marker misspecification than a randomized-block 
design, based on the flexibility and gains in power from the hierarchical model. Future 
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simulation studies are planned to demonstrate and quantify this assertion using the 
biomarker prevalences reported by Kim et al. (2011). All these points allow for such trials to 
be planned and budgeted for more easily using Bayesian hierarchical models and response-
AR.
The greatest benefit of our approach is that by jointly modeling efficacy of treatments in the 
Bayesian hierarchical model, improved statistical inferences can be made about the 
predictive or prognostic value of biomarkers over designs that focus on efficacy within or 
across patient subgroups. This will be critical for clinical contexts where integral biomarkers 
can be used to identify the proper study population for definitive phase III studies of 
efficacy. Finally, we note that as a conservative element to the adaptive approach, if the 
clinical data are missing or delayed (completely at random to treatment assignment), the AR 
will transition more slowly from ER.
Future efforts are to apply the Bayesian hierarchical structure to statistical models for other 
clinical endpoints that are continuous and right-censored. However, the advantages of 
adaptive design are maximized when endpoints can be assessed early. With the expansion of 
rationally identified therapeutic targets, the simultaneous identification of rational 
biomarkers naturally follows. Indeed, the FDA has released a draft guidance document “In 
Vitro Companion Diagnostic Devices” to encourage development of biomarkers (molecular 
or otherwise) as diagnostics for guiding treatment decisions and patient selection. The 
flexibility and efficiency of adaptive clinical trial designs provide important advances for 
guiding and accelerating this complex co-development process.
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Appendix: Sample R Code
####################
## Dependent function for simulation in R
####################
MCMCfun <- function(n_i, y, group2, theta.0, theta.1, phi) {
 require (msm)
 alpha <- phi[1]; sigma2 <- phi[2]; tau2 <- phi[3]
 mu <- pr.eff <- pr.stop <- pihat <- rmax <- rep(0, J* K)
 psi <- rep (0, J)
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 n.jk <- table (group2)
 n.j < - tapply (n.jk, rep(1:J, each=K), sum)
 sd.mu <- (n.jk + 1/sigma2) ˆ (-.5)
 sd.phi <- (n.j + 1/tau2) ˆ (-.5)
 for (b in 1:(n.burn+ (skip + 1) * n.iter)) {
 z <- rtnorm(n_i, mu[group2], lower = c(-Inf, 0) [1+y], upper = c(0, Inf) 
[1+y])
 mu <- rnorm(J* K, mean = (sigma2 * tapply(z,group2,sum) + 
rep(psi,each=K) ) /
 (sigma2 * n.jk + 1),sd=sd.mu)
 psi <- rnorm(J,mean = (tau2 * tapply(mu* n.jk,rep(1:J, each=K),sum) + 
alpha ) /
 (tau2 * n.j + 1),sd= sd.phi)
 if(b > n.burn & trunc((b-n.burn)/(skip+1)) == (b-n.burn)/ (skip + 1)){
 pr.eff <- pr.eff + (mu > qnorm(theta.0))/n.iter
 pr.stop <- pr.stop + (mu > qnorm(theta.1))/n.iter
 pihat <- pihat + pnorm(mu) / n.iter
 rmax <- rmax + (mu == rep(tapply(mu,rep(1:K,J),max), J)) / n.iter
 }
 }
return(list(pr.eff = pr.eff, pr.stop = pr.stop, pihat = pihat, rmax = rmax))
}
####################
## Simultations for Figures 2 and 3, and Table 1
## (parameterized for left-most column
####################
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J = 2; K = 2; ## Indexes for groups
prob.K = c(0.5,0.5) ## Proportion of genotype groups (length K)
p0 = 0.25; p1 = 0.2 ## Target response rates
off =0 ## Offset between target and true rate.
pi = c(p1 + off, p0, ## True response rates
 p0 , p1+off) ## ordered as trt(group)
phi.r = c(alpha = (qnorm(p0)+qnorm(p1))/2,
 sigma2 = 1, tau2 = 0.01) ## Hyperparameters for randomization
r.method =2 ## Mapping (1=ratio, 2=max)
phi.f = c(alpha = qnorm(p1),
 sigma2 = 1, tau2 = 0.01) ## Hyperparameters for futility
phi.e = c(alpha = qnorm(p0),
 sigma2 = 1, tau2 = 0.01) ## Hyperparameters for efficacy
delta.U = 0.9 ## Decision rule [efficacy]
delta.L = 0.025 ## Decision rule [stop]
n.burn = n.iter = 5000; skip =0 ## MCMC parameters
#### Simulation
set.seed(seed)
group <- assign <- group2 <- y <- rep(NA,Nmax)
stop1 <- rep(0,J* K); fail1 <- 0
theta.0 = rep(p0,J* K); theta.1 = rep(p1,J* K)
group[1:(J* K)] <- rep(1:K,J)
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assign[1:(J* K)] <- rep(1:J,each=K)
group2[1:(J* K)] <- group[1:(J* K)] + K * (assign[1:(J* K)]-1)
y[1:(J* K)] <- runif(J* K) < pi[group2[1:(J* K)]]
## Adaptive Randomization
i <- J* K
while((i < Nmax) & (fail1==0)){
 post.f <- MCMCfun(i,y[1:i], group2[1:i],theta.0, theta.1,phi.f) ## 1. Run 
MCMC for futility
 stop1[stop1==0] <- (post.f [[2]] [stop1==0] < delta.L) * i ## 2. Check 
futility in active arms
 drop <- tapply(stop1,rep(1:K,J),prod) ## 3. Drop groups with stopped arms
 if(prod(drop)) {fail1 <- 1} else { ## 4. If all arms not dropped
 if(sum(!drop)>1){ ## 4a. Draw new patients group
 group[i + 1] <- sample((1:K)[!drop], 1,prob=prob.K[!drop])
 } else group[i+1] <- (1:K)[!drop]
 post.r <- MCMCfun(i,y[1:i], group2[1:i],theta.0,theta.1,phi.r) ## 4b. Run 
MCMC for randomization
 if(r.method == 1){
 rand <- post.r[[3]]
 } else if(r.method == 2) rand <- post.r[[4]]
 rand[stop1>0] <- 0
 assign[i + 1] <- sample(1:J,1, prob=rand[rep(1:K,J) ==group[i + 1]]) ## 4c. 
Assign treatment
 group2[i + 1] <- group[i + 1] + K* (assign[i + 1]-1)
 y[1+i] <- runif(1) < pi[group2[1+i]] ## 4d. Simulate outcome
 post.e <- MCMCfun(i + 1,y[1:(i + 1)], group2[1:(i + 1)],theta.0,theta.
1,phi.e)
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 write(paste(c(i + 1, ## 4e. Output:
 table(group2[1:(1+i)]), #Sizes
 (post.e[[1]] > delta.U)* (stop1==0), # Dec of Eff
 (stop1>0), # Dec of Fut
 post.e[[3]], # PostMean of Eff
 rand), # Rand weights
 collapse=” “),outfile, append=T)
 print(paste(” “, i + 1, “patients analyzed”))
 }
 i <- i + 1
}
####################
## Simulation of PI3K trial design: Scenario #3: LumB ONLY
####################
## Parameters
Nmax = 200 ## Maximum possible total sample size
J = 2; K = 4 ## Indexes for groups
prob.K = c(0.161,0.393,0.200,0.244) ## Proportion of biomarker subgroups
pi = c(0.25,0.25,0.25,0.25, ## True response rates (length J * K)
 0.50,0.50,0.25,0.25) ## ordered as trt(group) -
r.method =2 ## Treatment effect mapping
phi.r = c(alpha = (qnorm(0.25)+qnorm(0.5))/2,
 sigma2 = 1,tau2 = 0.01) ## Hyperparameters for rand
phi.f = c(alpha = qnorm(0.5),
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 sigma2 = 1,tau2 = 0.01) ## Hyperparameters for fut
phi.e = c(alpha = qnorm(0.25),
 sigma2 = 1,tau2 = 100) ## Hyperparameters for eff
delta.U <- 0.90 ## Decision rule [success]
delta.L <- 0.02 ## Decision rule [stop]
lag <- 10 ## Lag - estimated accrual before ORR
Imin <- 0 ## Minimum number of patients before AR
cap <- 35 ## Maximum number of patients per arm
n.burn = n.iter = 5000; skip =0 ## MCMC parameters
#### Simulation
set.seed(seed)
theta.0 <- rep(0.25,J * K); theta.1 <- rep(0.5,J * K)
group <- sample(1:K,Nmax,replace=T,prob=prob.K)
stop1 <- stop2 <- rep(0,J * K); screen <- fail1 <- 0
assign <- y <- rep(NA,Nmax)
## Phase 1) ER phase until rule for interim monitoring triggered
 group2 <- factor(assign,levels=1:(J * K))
 i < - 0;
 while(i < (Nmax-lag-1) & (sum(table(group2)==0) | i < (Imin))){
 i <- i + 1
 assign[i] <- sample(1:J,1)
 group2[i] <- group[i] + K * (assign[i]-1)
 y[i] <- runif(1) < pi[group2[i]]
 }
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 start <- (i + lag)
 print(paste(“ “, start, “patients in ER phase”))
 assign[i+ (1:lag)] <- sample(1:J,lag,replace=T)
 group2[i+ (1:lag)] <- group[i+ (1:lag)] + K * (assign[i+ (1:lag)]-1)
 y[i+ (1:lag)] <- runif(lag) < pi[group2[i+ (1:lag)]]
## Phase 2) AR phase, arms are dropped by futility analysis
 while((i < (Nmax-lag)) & (!fail1)){
 post.f <- MCMCfun(i,y[1:i],group2[1:i],theta.0,theta.1, phi.f)
 stop1[stop1==0] <- (post.f[[2]][stop1==0] < delta.L) * i
 stop2 <- table(group2[1:(i + lag)]) >= cap
 drop <- tapply(stop1 + stop2,rep(1:K,J),prod)
 if(prod(drop)){ fail1 <- i } else {
 j <- i + 1 + lag
 if(drop[group[j]]){
 screen <- screen + 1
 c <- 1; while(c){
 group[j] <- sample((1:K),1,prob=prob.K)
 if(drop[group[j]]) screen <- screen + 1 else c <- 0
 }
 }
 post.r <- MCMCfun(i,y[1:i],group2[1:i],theta.0, theta.1,phi.r)
 if(r.method == 1){
 rand <- post.r[[3]]
 } else if(r.method == 2) rand <- post.r[[4]]
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 rand[(stop1>0) |stop2] <- 0
 assign[j] <- sample(1:J,1,prob=rand[rep(1:K,J) ==group [j]])
 group2[j] <- group[j] + K * (assign[j]-1)
 y[j] <- runif(1) < pi[group2[j]]
 post.e <- MCMCfun(j,y[1:j],group2[1:j],theta.0,theta.1, phi.e)
 print(paste(“ ”, j, “patients analyzed”))
 write(paste(c(j,screen, table(group2[1:j]), ## Total, screened and subgroup 
sizes
 (post.e[[1]] > delta.U) * (stop1==0), ## Decision of efficacy
 (stop1>0), ## Decision of futility
 rand), ## Randomiztion ratios
 collapse=“\t”),outfile, append=T)
 }
 i <- i + 1
}
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Schema for integral biomarker trials designs that incorporate randomized treatment arms, 
including randomized-block (left panel), marker-enrichment (top-right), and marker-directed 
designs (bottom-right).
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The average randomization ratio from N = 5 to N = 100 under the single marker scenario for 
the target subgroup (solid line) vs. nontarget subgroup (dotted-line). In each panel, 
trajectories are drawn for noninformative priors (τ−2 = 0.01, red) and for balanced priors 
(τ−2 = 100, green). Results are displayed for ratio-mapping (left panels) and max-mapping 
(right panels); and for true efficacy levels of π0 = 0.25 and π1 = 0.5 (top panels) and for π0 = 
0.05 and π1 = 0.2 (bottom panels).
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Operating characteristics of Bayesian adaptive vs. fixed staged designs. The probabilities of 
determining efficacy are shown for target samples sizes ranging from N = 5 to 100. In both, 
the single marker (left panels) and complementary marker (right panels) scenarios, effective 
treatment-marker combinations are shown in green, vs. ineffective combinations in red. 
Vertical lines show the target and expected sample sizes (dark and light gray) that give 80% 
power and control Type I error at 10% in four parallel Simon two-stage tests. Lower panels 
display the cumulative distribution function (CDF) of sample sizes for the parallel Simon 
design (gray) under each scenario, vs. sample sizes seen under simulation for adaptive 
designs (blue) with target N = 55 and 59, respectively.
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Schema for the adaptive randomized phase II to evaluate capecitabine (X) with and without 
a PI3K inhibitor across four biomarker-defined subgroups of ER+/Her2– breast cancer.
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Table 2
Hypothetical relationships between intrinsic subtype, PI3K mutation status, and efficacy of the inhibitor 
(π XP,k below). Subgroups with clinical benefit over capecitabine alone (π X,k = 0.25 in all subgroups) are 
highlighted in gray. The joint prevalence was reported by TheCancer Genome Atlas Network (2012), and 
accounts for inclusion into the luminal B* subgroup basal and Her2-enriched subtypes which are seen more 
rarely in ER+/Her2– disease by IHC
Luminal B* Luminal A
Prevalence PI3K mut. 16.1% PI3K wt. 39.3% PI3K mut. 20.0% PI3K wt. 24.4%
Global Null 0.25 0.25 0.25 0.25
No Biomarker 0.50 0.50 0.50 0.50
Single Biomarker
 Luminal B only 0.50 0.50 0.25 0.25
 PI3K mut. only 0.50 0.25 0.50 0.25
Joint Biomarker
 Either marker 0.50 0.50 0.50 0.25
 Both markers 0.50 0.25 0.25 0.25
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Table 3
Probabilities of concluding efficacy by treatment and biomarker subgroup under the six 
scenarios defined in Table 2. All effective treatments by subgroups per scenario are 
shaded in gray
Luminal B* Luminal A
PI3K mut. PI3K wt. PI3K mut. PI3K wt.
Global Null
XP 0.058 0.073 0.072 0.066
X 0.071 0.069 0.076 0.063
No Biomarker
XP 0.821 0.928 0.892 0.899
X 0.057 0.085 0.053 0.06
Luminal B only
XP 0.856 0.928 0.094 0.094
X 0.064 0.066 0.061 0.059
PI3K mt only
XP 0.870 0.085 0.909 0.069
X 0.074 0.059 0.07 0.055
Either marker
XP 0.847 0.923 0.884 0.085
X 0.061 0.074 0.068 0.072
Both markers
XP 0.874 0.075 0.067 0.074
X 0.076 0.066 0.057 0.072
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Table 4
Family-wise operating characteristics of the AR design vs. parallel Simon two-stage 
designs
P3 P4x P4xp P5
Global Null
 AR −NA− 0.748 0.760 0.575
 Simon −NA− 0.676 0.676 0.456
No Biomarker
 AR 0.625 0.771 −NA− 0.497
 Simon 0.527 0.676 −NA− 0.356
Luminal B only
 AR 0.798 0.786 0.820 0.536
 Simon 0.726 0.676 0.822 0.403
PI3K mt only
 AR 0.789 0.766 0.855 0.521
 Simon 0.726 0.676 0.822 0.403
Either marker
 AR 0.694 0.750 0.915 0.485
 Simon 0.618 0.676 0.907 0.379
Both markers
 AR 0.874 0.763 0.802 0.526
 Simon 0.852 0.676 0.745 0.429
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